A novel recurrent copy number loss region on 6q23.3 in MDS-related myeloid malignancy patients with stable survival conditions.

about

A novel recurrent copy number loss region on 6q23.3 in MDS-related myeloid malignancy patients with stable survival conditions.

Item

http://www.wikidata.org/entity/Q53366811

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A novel recurrent copy number ...... th stable survival conditions.

@en

A novel recurrent copy number ...... th stable survival conditions.

@nl

type

Item

label

A novel recurrent copy number ...... th stable survival conditions.

@en

A novel recurrent copy number ...... th stable survival conditions.

@nl

prefLabel

A novel recurrent copy number ...... th stable survival conditions.

@en

A novel recurrent copy number ...... th stable survival conditions.

@nl

P1476

A novel recurrent copy number ...... th stable survival conditions.

@en

P2093

Kun Chi

http://www.w3.org/2001/XMLSchema#string

Lan Xu

http://www.w3.org/2001/XMLSchema#string

Xuefeng Wang

http://www.w3.org/2001/XMLSchema#string

Yang Li

http://www.w3.org/2001/XMLSchema#string

P2860

Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Reduced c-Myb activity compromises HSCs and leads to a myeloproliferation with a novel stem cell basis

Mutation in TET2 in myeloid cancers

Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.

Clinical effect of point mutations in myelodysplastic syndromes

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.

An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines.

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

P304

2470-2479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1292357

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28394181

http://www.w3.org/2001/XMLSchema#string